Aromasin

Exemestane is chosen by users who want a steroidal AI with a milder lipid profile and who prefer the twice-weekly or less frequent dosing schedule. Some users also find it more controllable at low doses (6.25mg) when estrogen management needs are modest.

Use case: Estrogen control when a steroidal AI is preferred or when users want less interaction with SERMs.

Administration: Start low. Its effect can outlast the user’s expectations because it irreversibly disables aromatase.

Decision rule: Treat it like a precise tool, not a background supplement.

Stop or reduce if: low-estrogen symptoms develop or the user overshoots repeatedly.

The irreversible binding means a single dose reduces aromatase activity for the duration of that enzyme’s lifespan. Effect does not build as predictably as with anastrozole. Dosing 12.5–25mg every other day or every 3 days is common.

Exemestane is a “suicidal” or “type I” aromatase inhibitor; it binds irreversibly to the aromatase enzyme and permanently disables it. The body must synthesize new aromatase enzyme to restore aromatization, which takes days to weeks depending on turnover rate. This irreversible mechanism distinguishes it from anastrozole and letrozole, which compete reversibly for the binding site.

The practical consequence: if exemestane is overdosed and estrogen crashes, reducing or stopping the dose does not immediately allow estrogen to recover. The user must wait for new enzyme production. This makes overcorrection harder to fix quickly than with reversible AIs.

The upside: it has a mild androgenic activity (it is steroidal, derived from androstenedione) and is reported to have a more favorable effect on lipids than anastrozole. It does not produce the same degree of HDL suppression seen with some reversible AIs, though the difference in practice is modest.

Exemestane does not appear to reduce Tamoxifen effectiveness the way some data suggest anastrozole might. This has made it the preferred on-PCT AI choice for users who combine AI with SERM during the early PCT phase, though most users discontinue AI before starting SERM-only PCT.

Assuming that because the mechanism is “harder to reverse,” the dose should be more conservative. Users often under-dose exemestane relative to their aromatization load and wonder why estrogen is not controlled.

The opposite problem: escalating dose too quickly because results are not immediate. The irreversible binding creates a cumulative effect over days, the response from a dose change is not fully apparent for 3–5 days.

Compared with Arimidex, exemestane is less adjustable in the short term but has a slightly more favorable lipid profile. For users who need precise titration and fast correction, anastrozole is usually the better tool. For users with stable, predictable aromatization on an established cycle, exemestane’s dosing schedule can be more practical.